These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 29579856

  • 1. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Cintra-Cabrera M, Suárez-Benjumea A, Bernal-Blanco G, González-Roncero FM, Toapanta-Gaibor NG, Súñer-Poblet M, Pérez-Valdivia MÁ, Fernández-Cuenca F, Gentil-Govantes MÁ, Rocha-Castilla JL.
    Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D, Ogawa Y, Fujita H, Morita K, Sasaki H, Oishi Y, Higuchi H, Hatanaka K, Shinohara N.
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [Abstract] [Full Text] [Related]

  • 3. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 4. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM, Kwon CH, Joh JW, Ha YE, Sinn DH, Choi GS, Peck KR, Lee SK.
    PLoS One; 2015 Feb 15; 10(5):e0123554. PubMed ID: 25942443
    [Abstract] [Full Text] [Related]

  • 5. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 6. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A, Latif A, Kapoor V, Sohail A, Florita C, Georgescu A, Zangeneh T.
    Transplant Proc; 2018 Dec 27; 50(10):3756-3762. PubMed ID: 30586840
    [Abstract] [Full Text] [Related]

  • 7. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 27; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K, Greser A, Wanner C.
    Clin Transplant; 2007 Dec 27; 21(1):80-5. PubMed ID: 17302595
    [Abstract] [Full Text] [Related]

  • 9. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison MG.
    Transpl Infect Dis; 2016 Jun 27; 18(3):390-5. PubMed ID: 27037651
    [Abstract] [Full Text] [Related]

  • 10. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 Jun 27; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
    Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, Chandrasekar P, Haririan A.
    Clin Transplant; 2005 Apr 27; 19(2):273-8. PubMed ID: 15740567
    [Abstract] [Full Text] [Related]

  • 12. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011 Apr 27; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

  • 13. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J, Rotjanapan P, Watcharananan SP.
    Transplant Proc; 2017 Jun 27; 49(5):1048-1052. PubMed ID: 28583524
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 27; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 15. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E, Näf B, Müller TF, Wüthrich RP, Schachter T, von Moos S.
    Clin Transplant; 2021 Nov 27; 35(11):e14401. PubMed ID: 34181768
    [Abstract] [Full Text] [Related]

  • 16. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 27; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 17. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
    Peixoto M, Mascarenhas L, Cunha A, Dutra M, Miranda E, Silva I, Costa S, Galvão B, Cunha A.
    Antivir Ther; 2012 Apr 27; 17(3):585-8. PubMed ID: 22293247
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B, Zencke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Yalcinkaya F, Thiel F, Billing H, Pohl M, Fehrenbach H, Bruckner T, Tönshoff B.
    Transplantation; 2016 Apr 27; 100(4):862-70. PubMed ID: 26736017
    [Abstract] [Full Text] [Related]

  • 19. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation.
    Posadas Salas MA, Taber DJ, Chua E, Pilch N, Chavin K, Thomas B.
    Transpl Infect Dis; 2013 Dec 27; 15(6):551-8. PubMed ID: 24010993
    [Abstract] [Full Text] [Related]

  • 20. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
    Nawashiro Y, Shiraki K, Yamamoto S, Takizawa K, Sasada Y, Suehiro M, Miura K, Hattori M, Daikoku T, Hisano M.
    Transplant Proc; 2018 Dec 27; 50(10):3932-3936. PubMed ID: 30577289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.